Assessment and comparison of acute cardiac toxicity during high-dose cyclophosphamide and high-dose etoposide stem cell mobilization regimens with N-terminal pro-B-type natriuretic peptide

Transfusion and Apheresis Science

Volumn 50, Issue 1, 2014, Pages 46-52

  Ozkan, Hasan Atilla ^a   Bal, Cengiz ^b   Gulbas, Zafer ^a  

^a Anadolu Medical Center Hospital   (Turkey)

^b OSMANGAZI UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Cardiac toxicity; Cyclophosphamide; Etoposide; Mobilization chemotherapy; Natriuretic peptide

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DIURETIC AGENT; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MESNA; MITOXANTRONE; ANTINEOPLASTIC AGENT; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PLASMACYTOMA; PROTEIN BLOOD LEVEL; STEM CELL MOBILIZATION; YOUNG ADULT; COMPARATIVE STUDY; DRUG EFFECTS; HEART; HEART MUSCLE; HEMATOLOGIC NEOPLASMS; METABOLISM; PROCEDURES; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RISK; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARDIOTOXICITY; CYCLOPHOSPHAMIDE; ETOPOSIDE; FEMALE; HEART; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; RISK; ROC CURVE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84897022202     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2013.12.001     Document Type: Article

References (44)

1. Shipp M.A., Abeloff M.D., Antman K.H., et al. International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-hodgkin's lymphomas: report of the jury. J Clin Oncol 1999, 17:423-429.
2. Majhail N.S., Weisdorf D.J., Defor T.E., et al. Long-term results of autolous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006, 12:1065-1072.
3. Child J.A., Morgan J.M., Davies F.E., Owen R.G., Bell S.E., Hawkins K., et al. High dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003, 348:1875-1883.
4. Kupari M., Volin L., Suokas A., Timonen T., Hekali P., Ruutu T. Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmia, heart failure and autopsy findings. Bone Marrow Transplant 1990, 5:91-98.
5. Appelbaum F., Strauchen J.A., Graw R.G., Savage D.D., Kent K.M., Ferrans V.J., et al. Acute lethal carditis caused by high-dose combination chemotherapy: a unique clinical and pathological entity. Lancet 1976, 1:58-62.
6. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malingnant and nonmalignant hematologic diseases. Blood 1998, 91:756-763.
7. Breverman A.C., Antin J.H., Plappert M.T., Cook E.T., Lee R.T. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 1991, 9:1215-1233.
8. Zver S., Zadnik V., Bunc M., Rogel P., Cernelc P., Kozelj M. Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Int J Hematol 2007, 85:408-414.
9. Copelan E.A., Ceselski S.K., Ezzone S.A., et al. Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease. J Clin Oncol 1997, 15:759-765.
10. Krishnan A., Bhatia S., Slovak M.L., et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000, 95:1588-1593.
11. Albini A., Pennesi G., Donatelli F., Cammarota R., DeFlora S., Noonan D.M. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010, 102:14-25.
12. Sudoh T., Kangawa K., Minamino N., Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988, 332:78-81.
13. Mukoyama M., Nakao K., Hosoda K., Suga S., Saito Y., Ogawa Y. Brain natriuretic peptide as a novel cardiac hormone in humans. J Clin Invest 1991, 87:1402-1412.
14. Brunner-La Rocca H.P., Kaye D.M., Woods R.L., Hastings J., Esler M.D. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol 2001, 37:1221-1227.
15. Wang T.J., Larson M.G., Levy D., Benjamin E.J., Leip E.P., Omland T., et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004, 350:655-663.
16. Snowden J.A., Hill G.R., Hunt P., Carnoutsos S., Spearing R.L., Espiner E., et al. Assessment of cardiotoxicity during haematopoietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transplant 2000, 26:309-313.
17. Niwa N., Watanabe E., Hamaguchi M., Kodera Y., Miyazaki H., Kodama I., et al. Early and late elevation of plasma atrial and brain natriuretic peptides in patients after bone marrow transplantation. Ann Hematol 2001, 80:460-465.
18. Chung T., Lim W.C., Sy R., Cunningham I., Trotman J., Kritharides L. Subacute cardiac toxicity following autologous haematopoietic stem cell transplantation in patients with normal cardiac function. Heart 2008, 94:911-918.
19. Peres E., Levine J.E., Khaled Y.A., Ibrahim R.B., Braun T.M., Krijanovski O.I., et al. Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation. Bone Marrow Transplant 2010, 45:149-152.
20. Sagnella G.A. Measurement and significance of circulating natriuretic peptides in cardiovascular diseases. Clin Sci 1998, 95:519-529.
21. Clerico A. Pathophysiological and clinical relevance of circulating levels of cardiac natriuretic hormones: is their assay merely a marker of cardiac disease?. Clin Chem Lab Med 2002, 40:762-777.
22. Wannamethee S.G., Welsh P., Lowe G.D., Gudnason V., Di Angelantonio E., Lennon L., et al. N-terminal pro-brain natriuretic peptide is a more useful predictor of cardiovascular disease risk than c-reactive protein in older men with and without pre-existing cardiovascular disease. J Am Coll Cardiol 2011, 58:56-64.
23. Kinnunen P., Vuoltheenaho O., Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology 1993, 132:1961-1970.
24. Mair J. Biochemistry of B-type natriuretic peptide-where are we now?. Clin Chem Lab Med 2008, 46:1507-1514.
25. Waldo S.W., Beede J., Isakson S., Villard-Saussine S., Fareh J., Clopton P., et al. Pro-B-type natriuretic peptide levels in acute decompensated heart failure. J Am Coll Cardiol 2008, 51:1874-1882.
26. Haaf P., Balmelli C., Reichlin T., et al. N-terminal pro B-type natriuretic peptide in the early evaluation of suspected acute myocardial infarction. Am J Med 2011, 124:731-739.
27. Gharib M.I., Burnett A.K. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail 2002, 4:235-242.
28. Schimmel K.J., Richel D.J., van de Brink R.B., Guchelaar H.J. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 2004, 30:181-191.
29. Kuittinen T., Husso-Saastamoinen M., Sipola P., Vuolteenaho O., Ala-Kopsala M., Nousiainen T., et al. Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant 2005, 36:1077-1082.
30. Kuittinen T., Jantunen E., Vanninen E., Mussalo H., Vuolteenaho O., Ala-Kopsala M., et al. Cardiac effects within 3 months of BEAC high-dose therapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation. Eur J Haematol 2006, 77:120-127.
31. Rr P., Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008, 54:24-38.
32. Bujak M., Frangogiannis N.G. The role of IL-1 in the pathogenesis of heart disease. Arch Immunol Ther Exp 2009, 57:165-176.
33. Zver S., Zadnik V., Cernelc P., Kozelj M. Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation. Int J Hematol 2008, 88:227-236.
34. Roziakova L., Bojtarova E., Mistrik M., Dubrava J., Gergel J., Lankova N., et al. Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation. J Exp Clin Cancer Res 2012, 31:13-18.
35. Poutanen T., Tikanoja T., Riikonen P., Silvast A., Perkkiö M. Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children. J Clin Oncol 2003, 12:2349-2356.
36. Nevo I., Erlichman M., Algur N., Nir A. N-terminal pro B-type natriuretic peptide levels in infants and children with acute non-cardiac diseases. Isr Med Assoc J 2011, 13:420-424.
37. Mahindra A., Bolwell B.J., Rybicki L., et al. Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia. Bone Marrow Transplant 2011, 47(2):231-235.
38. Wood W.A., Whitley J., Moore D., Sharf A., Irons R., Rao K., et al. Chemomobilization with etoposide is highly effective in patients with multiple myeloma and overcomes the effects of age and prior therapy. Biol Blood Marrow Transplant 2011, 17:141-146.
39. Sobecks R.M., Daugherty C.K., Hallahan D.E., Laport G.F., Wagner N.D., Larson R.A. A dose escalation study of total body irradiation followed by high-dose etoposide and allogeneic blood stem cell transplantation for the treatment of advanced hematologic malignancies. Bone Marrow Transplant 2000, 25:807-813.
40. Van Besien K., Devine S., Wickrema A., et al. Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies. Bone Marrow Transplant 2003, 32:471-476.
41. Sandri M.T., Salvatici M., Cardinale D., Zorzino L., Passerini R., Lentati P., et al. N-terminal pro-Btype natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction ?. Clinical Chem 2005, 51:1405-1410.
42. Goldberg M.A., Antin J.H., Guinan E.C., Rappeport J.M. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 1986, 68:1114-1118.
43. Rudiger A., Gasser S., Fischler M., Hornemann T., von Eckardstein A., Maggiorini M. Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure. Crit Care Med 2006, 34:2140-2144.
44. Katoka K., Nannya Y., Iwata H., Seo S., Komano K., Takahashi T., et al. Plasma brain natriuretic peptide is associated with hepatic veno-occlusive disease and early mortality after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2010, 45:1631-1637.